U.S. Patent Issued for Champions Biotechnology's Lead Oncology Drug

BALTIMORE, Oct. 13 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc.
(OTC Bulletin Board: CSBR), a drug development company with a preclinical
platform able to predict clinical effectiveness, accelerate development and
enhance the value of oncology drugs, today announced that the United States
Patent and Trademark Office issued a patent on September 29, 2009 for the
company's tubulin inhibitors, including its lead compound SG410. U.S. Patent
No. 7,595,326 entitled "Synthesis of Novel Tubulin Polymerization Inhibitors:
Benzoylphenylurea (BPU) Sulfur Analogs" protects the Company's composition of
matter, pharmaceutical composition, and method of treatment for SG410. The
patent is owned by Champions Biotechnology.

"This patent solidifies Champions' intellectual property position on SG410. We
believe that SG410, in the new Neowater formulation we developed, has the
potential to significantly impact the treatment of cancer," said Doug Burkett,
Ph.D., President of Champions Biotechnology, Inc. "SG410 is Champions' first
internal compound and is currently undergoing Biomerk Tumorgraft(TM)
evaluation. The results of SG410 tests in our predictive platform are expected
to be available soon. We are also actively evaluating high potential
compounds to build our oncology drug pipeline and expect to in-license
additional drugs in the near future. Studies suggest that evaluations of
compounds through Biomerk Tumorgrafts will lead to more successful and
efficient clinical development."

For more information regarding Champions Biotechnology's growing business and
recent news, please visit www.championsbiotechnology.com.

About SG410
SG410 is an antimitotic inhibitor that was shown in Tumorgraft models to
target microtubule associated protein tau (MAPT) deficient tumors with
promising results as compared to a currently marketed and leading
chemotherapeutic drug. These antimitotic inhibitors target MAPT
(Microtubule-Associated Protein Tau) deficient tumors. In both in vitro and in
vivo models, SG410 has demonstrated promising activity against prostate and
pancreatic cancer.

About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced
preclinical platforms and tumor specific data to enhance and accelerate the
value of oncology drugs. The Company's Preclinical Platform is a novel
approach based upon the implantation of primary human tumors in immune
deficient mice followed by propagation of the resulting engraftments (Biomerk
Tumorgrafts(TM)) in a manner that preserves the biological characteristics of
the original human tumor. Early studies suggest that unlike traditional
xenografts, these Tumorgrafts closely reflect human cancer biology and their
response to drugs is predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug
candidates and to develop a portfolio of novel therapeutic candidates. As
drugs progress through early stage development, the Company plans to sell,
partner or license them to pharmaceutical and/or biotechnology companies, as
appropriate. The Company also offers its predictive preclinical platform and
tumor specific data to physicians for personalized patient care and to
companies for evaluation of oncology drugs in models that integrate prognostic
testing with biomarker discovery.
www.championsbiotechnology.com
www.personalizedcancertreatment.com

This press release contains "forward-looking statements" (within the meaning
of the Private Securities Litigation Act of 1995) that inherently involve risk
and uncertainties. Champions Biotechnology generally uses words such as
"believe," "may," "could," "will," "intend," "expect," "anticipate," "plan,"
and similar expressions to identify forward-looking statements. One should not
place undue reliance on these forward-looking statements. The Company's actual
results could differ materially from those anticipated in the forward-looking
statements for many unforeseen factors. See Champions Biotechnology's Form
10-K for the fiscal year ended April 30, 2009 for a discussion of such risks,
uncertainties and other factors. Although the Company believes the
expectations reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are made, and
Champions Biotechnology's future results, levels of activity, performance or
achievements may not meet these expectations. The Company does not intend to
update any of the forward-looking statements after the date of this press
release to conform these statements to actual results or to changes in
Champions Biotechnology's expectations, except as required by law.

For more news and information on Champions Biotechnology, Inc., please visit
www.IRGnews.com/coi/CSBR where you can find the CEO's video, a fact sheet on
the company, investor presentations, and more.

CONTACT:
The Investor Relations Group, Inc.
James Carbonara
+1-212-825-3210

SOURCE Champions Biotechnology, Inc.

The Investor Relations Group, Inc., James Carbonara, +1-212-825-3210